Q-Sera Pty Ltd is an Australian venture-backed private company with an industry-experienced CEO and a founding research team of international experts on snake venom proteins that has developed a gold standard serum tube. Commercialisation is ongoing, with a license agreement signed in 2021 with Terumo Corporation, Japan. Achievements Identification and engagement of a US-based investment bank to assist with commercialisation. Granting of Intellectual Property (IP) portfolio in… Show more Q-Sera Pty Ltd is an Australian venture-backed private company with an industry-experienced CEO and a founding research team of international experts on snake venom proteins that has developed a gold standard serum tube. Commercialisation is ongoing, with a license agreement signed in 2021 with Terumo Corporation, Japan. Achievements Identification and engagement of a US-based investment bank to assist with commercialisation. Granting of Intellectual Property (IP) portfolio in all major jurisdictions. Engaged potential partners for Q-Sera’s technology in the US, Europe and Japan at technical and commercial levels.Delivered successful investor presentations and secured R & D rebates and government grants to ensure funds for operations. Governance including Board meetings, ASIC management, Financials, audits and investor management. Managed the development of a recombinant protein from construct design to scale-up including characterisation and purification processes. Managed a Queensland-based R & D team, as well as university research contracts and external finance and Intellectual Property functions in a hands-on capacity.Established a Data Room with an active Due Diligence process. Show less

As an Independent Consultant, I worked with Commercialisation Australia (now Accelerating Commercialisation) to assist Life Science start-ups.

CSL Limited is the parent company of global biotechnology leader CSL Behring, the world’s largest producer of therapeutics from human plasma, and a manufacturer of recombinant clotting factors to help patients globally. The company’s Australian operation manufactures a range of life-saving plasma-derived therapies under contract to the National Blood Authorities of Australian and regional communities. This was an interim Program management role in which I was chiefly responsible for… Show more CSL Limited is the parent company of global biotechnology leader CSL Behring, the world’s largest producer of therapeutics from human plasma, and a manufacturer of recombinant clotting factors to help patients globally. The company’s Australian operation manufactures a range of life-saving plasma-derived therapies under contract to the National Blood Authorities of Australian and regional communities. This was an interim Program management role in which I was chiefly responsible for restructuring the IT implementation program including systems such as SAP and Quality, as part of the integration of CSL’s Australian plant into the global Behring business.Achievements• Performed risk assessments and oversaw internal governance requirements and Change Management plans to ensure a smooth transition of changed workflows and IT systems. • Worked directly with the IT Project Manager to co-manage implementation of the SAP ERP system. • Worked with global functions to finalise timing for IT implementations and develop resourcing plans across all business functions. The plan covered electronic Quality Management, Enterprise Resource Planning and Customer Relationship Management systems. Show less

This role was based at CSL Behring’s Coagulation centre of excellence in Marburg, Germany. I was chiefly responsible for managing the cross-cultural Global Coagulation Team including direct reports such as the Global Marketing and Medical Directors and Communications Manager; and leadership of cross-functional Global Business Teams. Leadership of global teams to manage the strategic development and global product support for the USD $1 billion Coagulation portfolio, including plasma-derived and… Show more This role was based at CSL Behring’s Coagulation centre of excellence in Marburg, Germany. I was chiefly responsible for managing the cross-cultural Global Coagulation Team including direct reports such as the Global Marketing and Medical Directors and Communications Manager; and leadership of cross-functional Global Business Teams. Leadership of global teams to manage the strategic development and global product support for the USD $1 billion Coagulation portfolio, including plasma-derived and recombinant clotting factors for congenital bleeding disorders, and drafting Strategic Plans. Achievements• Collaborated with R&D and Clinical on pipeline development and clinical trial design and recruitment.• CSL Commercial lead for a USD $500 million global licensing contract, with responsibility for pipeline product Business Cases; and Commercial lead for Due Diligence process on potential product acquisition. • Oversaw the development of Strategic Plans at Australian, Western European and Global levels. Coordinated Commercial input to five-year Strategic Planning including budget management. • Developed the global product and lifecycle management strategies, including the provision of core promotional and scientific literature for Global Commercial Operations.• Managed Commercial input to CSL’s R&D decision gate process, including provision of Target Product Profiles.• Led development of global Communication and Publication plans for CSL’s recombinant pipeline and technology platform, based on clear positioning, key messages and brand vocabularies to ensure consistent communication internally and externally. • Collaborated with stakeholders influential in Europe and more globally, including clinicians, clinical organisations and patient advocacy groups. • Experienced with competency-based performance management, recruitment and staff development. Show less

Regional role operating out of CSL Behring’s UK Office leading the development of the coagulation franchise for Western Europe and provided strategic direction for the marketing of the coagulation and acquired bleeding portfolios through Global Business Teams. My team’s efforts contributed substantially to the company’s achievement of 10 per cent top-line growth. Achievements• By liaising with the nine affiliates representing 14 countries, developed and implemented the first… Show more Regional role operating out of CSL Behring’s UK Office leading the development of the coagulation franchise for Western Europe and provided strategic direction for the marketing of the coagulation and acquired bleeding portfolios through Global Business Teams. My team’s efforts contributed substantially to the company’s achievement of 10 per cent top-line growth. Achievements• By liaising with the nine affiliates representing 14 countries, developed and implemented the first regional strategic plans as a link between global five-year strategic planning and annual country marketing planning resulting in the increased efficiency of regional budget spends; and a realignment of vision and consistency of company and brand communication. • Developed Acquired Bleeding Market strategy based on new treatment paradigm, replacing general blood product administration with targeted plasma concentrates such as fibrinogen.• Working with Medical Affairs, commenced collection and review of European country- and regional-level clinical trial funding data, resulting in transparency and regional consideration of pharmacovigilance and budget effectiveness, a strategy that was then adopted globally. Show less

As Senior Product Manager, I worked within Australian Red Cross Blood Service and National Blood Authority contracts to provide strategic development and commercial support to a portfolio of plasma-derived therapies for congenital and acquired bleeding disorders. I also provided input to the Asian office and Global Business Team for campaigns and new product launches. Additional Achievements• Increased sales of an existing product by 50 per cent over 18 months by facilitating an… Show more As Senior Product Manager, I worked within Australian Red Cross Blood Service and National Blood Authority contracts to provide strategic development and commercial support to a portfolio of plasma-derived therapies for congenital and acquired bleeding disorders. I also provided input to the Asian office and Global Business Team for campaigns and new product launches. Additional Achievements• Increased sales of an existing product by 50 per cent over 18 months by facilitating an update of Australian and New Zealand clinical practice guidelines. • Strategic development of an Australian product to the global benchmark involving new indications, publications and packaging systems, working with an internal team on regulatory and launch strategies for Europe to achieve ongoing local market support, regional expansion and the 2014 European launch. • Drove a company-wide packaging review project resulting in an ongoing packaging working group that developed and launched a significantly improved reconstitution system across the Asia Pacific region. • Led cross-functional task forces to manage critical manufacturing issues, resulting in retention of supply and market position. • Became first Senior Management-level employee to be accepted into the CSL Global Leadership Program. Show less

As the Senior Product Manager at Sigma Pharmaceuticals, I managed Specialist, Primary Care and Pharmacy portfolios. Focussing on Cardiovascular, Anti-Infective and Ophthalmic therapeutic areas with $45 million in sales and an $800k spend, I successfully marketed and forecasted over 100 products, as well as assumed responsibility for brand development with GP and Specialist products and managed a specialist sales team. Additional Achievements• Successfully launched Klacid… Show more As the Senior Product Manager at Sigma Pharmaceuticals, I managed Specialist, Primary Care and Pharmacy portfolios. Focussing on Cardiovascular, Anti-Infective and Ophthalmic therapeutic areas with $45 million in sales and an $800k spend, I successfully marketed and forecasted over 100 products, as well as assumed responsibility for brand development with GP and Specialist products and managed a specialist sales team. Additional Achievements• Successfully launched Klacid (antibiotic), licensed from Abbott Australasia, with new campaign within three months, achieving national growth of 37 per cent after 18 months during negative growth period. Show less

Working with business functions in developing pharmaceuticals, emulsion systems and industrial products, I designed and developed a successful range of cough and cold products by collaborating with marketing and pharmacy professionals.